Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin Extract as Adjuvant Therapy in Schizophrenia
NCT07523256Completed
- Start
- Nov 2025
- Primary completion
- Jan 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised trial of curcumin in schizophrenia (2 arms). Primary endpoints: Serum Interleukin-1 Beta Levels at 8 weeks and Quality of Life at 8 weeks. Started Nov 2025; status: completed.
02
Drugs
curcumin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07523256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523256.